Answers are grounded in this paper and cite their sources.
Available treatments for relapsed/refractory multiple myeloma (RRMM) include multiclass triplet regimens such as lenalidomide and dexamethasone (Rd backbone) plus ixazomib (proteasome inhibitor [PI]; I) or daratumumab (monoclonal antibody; D). Although prior real-world studies compared PI-Rd triplets, this research extends those findings by comparing health care costs of a PI-based and a monoclonal antibody-based triplet, IRd and DRd, in patients with RRMM in the United States.
No takes yet. Share an insight, caveat, or question.
Ailawadhi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: